Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Change in Cash (2017 - 2025)

Historic Change in Cash for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to -$1.1 million.

  • Puma Biotechnology's Change in Cash fell 109736.84% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.7 million, marking a year-over-year increase of 863.87%. This contributed to the annual value of -$15.4 million for FY2024, which is 29490.11% down from last year.
  • Latest data reveals that Puma Biotechnology reported Change in Cash of -$1.1 million as of Q3 2025, which was down 109736.84% from -$8.4 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Change in Cash registered a high of $25.2 million during Q3 2022, and its lowest value of -$25.9 million during Q3 2021.
  • For the 5-year period, Puma Biotechnology's Change in Cash averaged around -$2.2 million, with its median value being -$1.8 million (2022).
  • Per our database at Business Quant, Puma Biotechnology's Change in Cash crashed by 307803.68% in 2021 and then surged by 22990.34% in 2023.
  • Over the past 5 years, Puma Biotechnology's Change in Cash (Quarter) stood at -$816000.0 in 2021, then tumbled by 115.56% to -$1.8 million in 2022, then soared by 229.9% to $2.3 million in 2023, then fell by 14.4% to $2.0 million in 2024, then plummeted by 158.13% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q3 2025, -$8.4 million for Q2 2025, and -$6.2 million during Q1 2025.